Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Mydecine Innovations Group Inc (MYCOF) Message Board

COVID-19 Stress May Cause Onset of PTSD New res

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 160
(Total Views: 249)
Posted On: 02/08/2022 4:53:16 PM
Avatar
Posted By: NetworkNewsWire
COVID-19 Stress May Cause Onset of PTSD

New research has discovered that traumatic stress associated with the coronavirus may be used to predict post-traumatic stress disorder. The researchers found a link between PTSD and COVID traumatic stress, noting that it was stronger in people who had repeatedly experienced past trauma.

In their report, the researchers noted that their findings were true across almost all racial groups, excluding Asian Americans.

The lead author of the study, Professor Jeff Ashby, has specialized in counseling and psychological services. He stated that despite many individuals being insulated from economic hardship and deaths associated with the pandemic, there was a universal experience of social isolation, fear and concern for other people. He explained that the researchers had found that the experience of the coronavirus was a traumatic stress, noting that it was a traumatic experience in itself and wasn’t just triggering earlier trauma.

For their study, the researchers administered a survey to more than 700 individuals that assessed the possible interaction of ethnicity/race, cumulative trauma and coronavirus traumatic stress in the prediction of symptoms of post-traumatic stress disorder. They made use of a COVID-19 Traumatic Stress Scale that was recently validated to measure the impact of the pandemic as related to the fear or threat of infection and subsequent death.

On a general scale, the study revealed a significant and positive link between symptoms of post-traumatic stress disorder and COVID traumatic stress, which suggests that the coronavirus pandemic was a unique traumatic stressor. They also discovered a link between high levels of cumulative trauma and symptoms of PTSD in all racial groups, excluding Asian Americans.

Ashby explained that their findings alluded to the existence of a relationship between PTSD and COVID traumatic stress and another between PTSD and cumulative trauma, which meant that individuals with more cumulative trauma were more likely to experience coronavirus as a traumatic stressor.

The researchers found that higher cumulative trauma levels didn’t worsen symptoms of post-traumatic stress disorder in Asian Americans who experienced COVID traumatic stress, noting that the relationship between symptoms of PTSD, traumatic stress and COVID wasn’t affected by prior trauma in this particular group. The researchers theorize that the increased discrimination and violence against Asian Americans during the pandemic may have reduced the effect of COVID-19 specific trauma on their symptoms of PTSD.

Ashby noted that the group’s results highlighted the importance of assessing subgroups in the community for possible buffering or aggravating effects of COVID stress on mental health outcomes of individuals.

The study’s findings were reported in the “Journal of Community Psychology.”

As cases of PTSD rise, the demand for new remedies, including those being developed by companies such as Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF), will increase.

NOTE TO INVESTORS: The latest news and updates relating to Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) are available in the company’s newsroom at https://ibn.fm/MYCOF

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer



(0)
(0)




Mydecine Innovations Group Inc (MYCOF) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us